KCNT1-  related epilepsy: An international multicenter cohort of 27 pediatric cases by Borlot, Felippe et al.
Epilepsia. 2020;61:679–692.    | 679wileyonlinelibrary.com/journal/epi
Received: 24 October 2019 | Revised: 2 February 2020 | Accepted: 24 February 2020
DOI: 10.1111/epi.16480  
F U L L - L E N G T H  O R I G I N A L  R E S E A R C H
KCNT1-related epilepsy: An international multicenter cohort of 
27 pediatric cases
Felippe Borlot1  |   Ahmed Abushama1 |   Nadine Morrison-Levy1,2 |   Puneet Jain1,3 |   
Kollencheri Puthenveettil Vinayan4 |   Musaad Abukhalid5 |   Hesham M. Aldhalaan5 |   
Hanin S. Almuzaini5 |   Sheffali Gulati6 |   Tova Hershkovitz7 |   Ramesh Konanki8 |   
Lokesh Lingappa8 |   Aimee F. Luat9 |   Shatha Shafi10 |   Brahim Tabarki10 |    
Maya Thomas11 |   Sangeetha Yoganathan11 |   Majid Alfadhel12,13  |   Ravindra Arya14,15  | 
Elizabeth J. Donner1 |   Salleh N. Ehaideb12 |   Vykuntaraju K. Gowda16 |    
Vivek Jain17 |   Priyanka Madaan18 |   Kenneth A. Myers19,20,21  |   Hiroshi Otsubo1 |   
Prateek Panda6 |   Jitendra K. Sahu18  |   Letícia P. B. Sampaio22 |   Suvasini Sharma23  | 
Elisabeth Simard-Tremblay19,20 |   Maria Zak1 |   Robyn Whitney1
1Division of Neurology, Department of Paediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada
2Children's Hospital of Eastern Ottawa, Ottawa, Ontario, Canada
3Division of Pediatric Neurology, Department of Pediatrics, Danat Al Emarat Hospital for Women and Children, Abu Dhabi, United Arab Emirates
4Department of Pediatric Neurology, Amrita Institute of Medical Sciences, Cochin, India
5Department of Neurosciences, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
6Child Neurology Division, Department of Pediatrics, Center of Excellence & Advanced Research on Childhood Neurodevelopmental Disorders, All India 
Institute of Medical Sciences, New Delhi, India
7Genetic Institute, Rambam Medical Center, Haifa, Israel
8Department of Neurology, Rainbow Children's Hospital, Hyderabad, India
9Detroit Medical Center, Children's Hospital of Michigan, Wayne State University School of Medicine, Detroit, Michigan
10Division of Neurology, Department of Pediatrics, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
11Pediatric Neurology, Department of Neurological Sciences, Christian Medical College, Vellore, India
12King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, Ministry of 
National Guard-Health Affairs, Riyadh, Saudi Arabia
13Division of Genetics, Department of Pediatrics, King Abdulaziz Medical City, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia
14Division of Neurology, Comprehensive Epilepsy Center, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
15Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio
16Indira Gandhi Institute of Child Health, Bangalore, India
17Santokba Durlabhji Hospital, Jaipur, India
18Pediatric Neurology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India
19Division of Neurology, Department of Pediatrics, Montreal Children's Hospital, McGill University Health Centre, Montreal, Quebec, Canada
20Department of Neurology & Neurosurgery, McGill University Health Centre, Montreal, Quebec, Canada
21Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
22Department of Neurology, Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil
23Neurology Division, Department of Pediatrics, Lady Harding Medical College and Kalawati Saran Children's Hospital, New Delhi, India
Wiley Periodicals, Inc.  
© 2020 International League Against Epilepsy
680 |   BORLOT eT aL.
Correspondence
Robyn Whitney, The Division of 
Neurology, The Hospital for Sick Children, 




Objective: Through international collaboration, we evaluated the phenotypic as-
pects of a multiethnic cohort of KCNT1-related epilepsy and explored genotype-
phenotype correlations associated with frequently encountered variants.
Methods: A cross-sectional analysis of children harboring pathogenic or likely path-
ogenic KCNT1 variants was completed. Children with one of the two more common 
recurrent KCNT1 variants were compared with the rest of the cohort for the presence 
of particular characteristics.
Results: Twenty-seven children (15 males, mean age = 40.8 months) were included. 
Seizure onset ranged from 1  day to 6  months, and half (48.1%) exhibited devel-
opmental plateauing upon onset. Two-thirds had epilepsy of infancy with migrat-
ing focal seizures (EIMFS), and focal tonic seizures were common (48.1%). The 
most frequent recurrent KCNT1 variants were c.2800G>A; p.Ala934Thr (n = 5) and 
c.862G>A; p.Gly288Ser (n  =  4). De novo variants were found in 96% of tested 
parents (23/24). Sixty percent had abnormal magnetic resonance imaging (MRI) 
findings. Delayed myelination, thin corpus callosum, and brain atrophy were the 
most common. One child had gray-white matter interface indistinctness, suggest-
ing a malformation of cortical development. Several antiepileptic drugs (mean = 
7.4/patient) were tried, with no consistent response to any one agent. Eleven tried 
quinidine; 45% had marked (>50% seizure reduction) or some improvement (25%-
50% seizure reduction). Seven used cannabidiol; 71% experienced marked or some 
improvement. Fourteen tried diet therapies; 57% had marked or some improvement. 
When comparing the recurrent variants to the rest of the cohort with respect to de-
velopmental trajectory, presence of EIMFS, >500 seizures/mo, abnormal MRI, and 
treatment response, there were no statistically significant differences. Four patients 
died (15%), none of sudden unexpected death in epilepsy.
Significance: Our cohort reinforces common aspects of this highly pleiotropic 
entity. EIMFS manifesting with refractory tonic seizures was the most common. 
Cannabidiol, diet therapy, and quinidine seem to offer the best chances of seizure 
reduction, although evidence-based practice is still unavailable.
K E Y W O R D S
cannabidiol, epilepsy of infancy with migrating focal seizures, KCNT1, ketogenic diet, microcephaly, 
quinidine
1 |  INTRODUCTION
KCNT1 encodes a ligand-gated potassium channel, which 
is activated by intracellular sodium binding (also called 
SLACK, SLO2.2, KC4.1). KCNT1 has several functions, 
which include regulating neuronal firing rate, contributing to 
the slow hyperpolarization after repetitive firing, and it also 
has an important role in neuronal response to hypoxia.1‒3 
Gain-of-function effects produce higher action potential fir-
ing frequency due to faster action potential repolarization and 
increased fast afterhyperpolarization.4 KCNT1 channels are 
widely expressed in the central nervous system and are found 
in the olfactory bulb, brainstem, and hippocampal and corti-
cal embryonic neurons.1,2,5
Gain-of-function KCNT1 pathogenic variants are known 
to cause pleiotropic effects, and a number of epilepsy phe-
notypes have been described: (1) epilepsy of infancy with 
migrating focal seizures (EIMFS)1,6; (2) a severe form of 
autosomal dominant sleep-related hypermotor epilepsy 
(ADSHE)7; (3) early onset epileptic encephalopathy (EOEE; 
ie, Ohtahara syndrome, West syndrome, and unclassified 
EOEE)8; (4) temporal lobe epilepsy with intellectual dis-
ability9; and (5) myoclonic-atonic epilepsy.10 Although 
most patients harboring KCNT1 pathogenic variants have no 
causative underlying structural brain abnormalities, patients 
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with ADSHE may rarely exhibit malformations of cortical 
development.11
There have been inconsistent data with respect to clini-
cal efficacy of quinidine (a broad-spectrum potassium chan-
nel blocker) in patients with EIMFS. Unblinded assessment 
of seizure reduction may range from complete to no re-
sponse.12‒17 Overall, half of EIMFS or EOEE patients will 
have no response to quinidine, and only 20% may benefit 
with at least a 50% seizure reduction.18 The main adverse 
effect attributed to quinidine therapy is cardiotoxicity with 
prolonged QTc interval and arrhythmias, but sedation, ele-
vated liver function tests, rash, and skin discoloration have 
also been described.18,19
We sought to evaluate the clinical aspects, including 
phenotypic presentation, electroencephalogram (EEG), neu-
roimaging, and response to pharmacological and nonpharma-
cological therapies of a multiethnic cohort of children with 
pathogenic or likely pathogenic KCNT1 variants. Despite the 
high pleiotropy and heterogeneity associated with KCNT1-
related epilepsies, we also aimed to explore any possible 
phenotype-genotype correlations associated with the most 
common identified variants.
2 |  MATERIALS AND METHODS
2.1 | Patients and institutional review board 
approval
Ethics approval for the study was granted by the Research 
Ethics Board at the Hospital for Sick Children, Toronto, 
Ontario, Canada (REB #1000061319) and the other partici-
pant centers, as per the respective hospital policies. Children 
were enrolled in the study after consent was obtained from 
legal guardians, unless the local board institution waived 
the need to obtain informed consent from a given center. 
Recruitment started within the Division of Neurology at the 
Hospital for Sick Children, which was the coordinating re-
search site. Henceforth, an international collaborative net-
work joined the study, allowing us to recruit patients from 
Brazil, Canada, India, Israel, Saudi Arabia, and the USA. 
All mutations were identified by commercial gene panels or 
whole exome sequencing.
2.2 | Study design, and inclusion and 
exclusion criteria
Inclusion criteria for this retrospective case series study were 
(1) age 18  years or younger; (2) diagnosed with KCNT1-
related epilepsy at any point before September 2018; and (3) 
pathogenic or likely pathogenic KCNT1 variants (class 5 or 
4), according to the American College of Medical Genetics 
and Genomics (ACMG),20,21 regardless of the phenotypic 
presentation. The exclusion criteria were (1) harboring 
KCNT1 variants of uncertain significance (VUS) or benign 
variants and (2) failure to gather enough data for phenotypic 
characterization.
2.3 | Data collection, analysis, and 
interpretation
Study data were collected, stored, and managed using the 
REDCap (Research Electronic Data Capture) secure elec-
tronic data capture tool at the Hospital for Sick Children.22,23 
Data abstraction protocol included demographics, age of 
presentation, first symptom developed by the patient, age at 
seizure onset, seizure type(s), presence of known epilepsy 
syndrome, developmental history, neurological/psychiatric/
systemic comorbidities, genotype and inheritance (if avail-
able), EEG reports, neuroimaging abnormalities, pharma-
cological and nonpharmacological treatment, and treatment 
response. For each treatment modality, the following op-
tions were gathered from caregivers and clinicians: (1) sei-
zure freedom, (2) marked improvement (ie, >50% reduction 
in seizures), (3) some improvement (ie, 25%-50% seizure 
reduction), (4) minimal improvement (ie, <25% seizure re-
duction), (5) no improvement, and (6) worsening of seizures. 
In addition, tolerability, adverse effects, reason for discon-
tinuation of therapy, and duration of therapies were gathered. 
Data were summarized using descriptive statistics, including 
mean, median, range, and standard deviation (SD) for con-
tinuous variables and percentage for categorical variables.
Clinical genetic testing (ie, through gene panels or whole 
exome sequencing) was performed through different compa-
nies internationally, using their specific protocols to obtain 
Key Points
• KCNT1-related epilepsy in children usually mani-
fests as early onset refractory focal tonic seizures 
and EIMFS
• Most children will become nonambulatory, non-
verbal, hypotonic, and spastic, with acquired mi-
crocephaly and cortical visual impairment
• Supportive MRI findings include delayed myeli-
nation, thin corpus callosum, brain atrophy, and 
malformations of cortical developmental
• There have been no well-established genotype-
phenotype–specific correlations so far
• Despite the lack of evidence-based practice, ke-
togenic diet and quinidine are well tolerated and 
may help with seizure reduction
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genomic DNA from blood. Testing of family members was 
performed according to clinical indication and/or availabil-
ity using Sanger sequencing in nearly all cases. Variants of 
uncertain significance, and benign and likely benign variants 
in other genes, as well as heterozygous pathogenic variants 
detected in genes associated with autosomal recessive condi-
tions, were considered out of the scope of the study and will 
not be reported.
To address the second aim of the study (ie, to determine 
phenotype-genotype correlations associated with more fre-
quently encountered variants), we performed the chi-square 
test (IBM SPSS Statistics v20.0) to compare the presence 
of specific findings (such as developmental plateauing, 
presence of EIMFS, reported seizure frequency > 500/mo, 
abnormal magnetic resonance imaging [MRI]) in the most 
frequently encountered KCNT1 variants found in our cohort 
(ie, 2800G>A; p.Ala934Thr and c.862G>A; p.Gly288Ser). 
In addition, the chi-square test was used to compare children 
with and without these variants, with respect to treatment re-
sponses to quinidine, diet therapy, and cannabidiol (CBD). 
Moreover, given the previous literature data suggesting that 
an earlier age at onset of quinidine therapy could result in a 
better response, we compared the age at initiation of quinidine 
therapy to the seizure reduction response using Spearman ρ 
calculator. Statistically significant correlations were consid-
ered positive if P < .05.
All data were reviewed by two authors from the main re-
search site for completeness; whenever incomplete or unclear 
information was noted, further clarification was sought from 
the contributing center. Individual genetic results (KCNT1 
variants) obtained from each center were checked and reclas-
sified (if required) in accordance with the ACMG criteria.20,21 
If, on reclassification, patients were found to have VUS or 
benign variants, they were then subsequently excluded from 
the analysis.
3 |  RESULTS
Thirty children were initially recruited from all centers. 
However, three patients were excluded upon review, as their 
KCNT1 variants were classified as VUS. Our cohort was 
composed of 27 children, 15 males and 12 females (ratio = 
1.25), current mean age = 40.8 months (SD = 28.3, median = 
38 months). Three patients were previously published (Cases 
15, 16, and 25),24,25 and 24 children are newly reported. For 
all children, seizures were the first concern that brought them 
to attention of a neurologist, with age at onset of seizures 
ranging from 1 day to 6 months of life (mean = 1.7 months, 
SD = 1.7, median = 1 month). Nevertheless, the mean age for 
a definitive diagnosis of KCNT1-related epilepsy was later, 
at mean of 18.8 months, SD = 20.1 (median = 10 months). 
Developmental trajectory was characterized by plateauing 
in nearly half of children (48.1%, 13/27) upon seizure onset, 
whereas 22.2% (6/27) had slow developmental gains, and 
22.2% (6/27) had developmental regression, followed by ei-
ther slow gains or plateauing.
Recurrent KCNT1 variants were reported in 18 patients. 
The most common KCNT1 variants were (1) c.2800G>A; 
p.Ala934Thr, (2) c.862G>A; p.Gly288Ser, and (3) 
c.1421G>A; p.Arg474His. These variants were, respec-
tively, seen in five (Cases 4, 8, 16, 24, and 27), four (Cases 
7, 9, 10, and 11), and three (Cases 6, 17, and 20) children. 
In addition, (4) c.1283G>A; p.Arg428Gln (Cases 1 and 23), 
(5) c.1420C>T; p.Arg474Cys (Cases 13 and 22), and (6) 
c.2849G>A; p.Arg950Gln (Cases 3 and 15) were found in 
two children each. From the nine nonrecurrent KCNT1 vari-
ants found in this cohort, four have not been previously re-
ported in the literature (Cases 2, 12, 14, and 18). Case 12's 
nucleotide variant (c.1130G>C) is novel; however, a nucle-
otide variant affecting the same amino acid (c.1129T>A; p.
Cys377Ser) has been reported in a patient presenting with 
EIMFS.26
Parental testing was completed in 24 of the 27 families, 
and 23 children (95.8%, 23/24) were found to have de novo 
variants. Despite having a de novo variant, six of the 23 chil-
dren (26%, 6/23) with a de novo variant had a positive fam-
ily history of seizures. We had only limited information on 
the specific epilepsy syndromes in the affected relatives: (1) 
Case 3's maternal great uncle had unclassified epilepsy; (2) 
three third cousins of Case 9 had recurrent seizures in adult-
hood; (3) Case 14's grandmother had unprovoked seizures in 
adulthood, and this maternal grandmother's sister had febrile 
seizures in childhood; (4) Case 15's paternal grandfather's 
brother had seizures in childhood only; (5) a paternal first 
cousin of Case 16 had seizures, and there is also a history of 
febrile seizures in this patient's second cousins; and finally 
(6) Case 26's father had recurrent seizures attributed to a pre-
vious history of traumatic brain injury. Only one child (Case 
10) presented with an inherited variant from an unaffected 
parent. Case 10's mother has no neurological manifestations, 
but is heterozygous for the variant c.862G>A; p.Gly288Ser. 
Consanguinity was reported in four families from Saudi 
Arabia, Cases 5, 6, 7, and 8, and three of these four variants 
(c.1885A>G, p.Lys629Glu; c.862G>A, p.Gly288Ser; and 
c.2800G>A; p.Ala934Thr) were found to be de novo. The 
parents of Case 6 were not available for testing (unknown 
inheritance of the variant c.1421G>A; p.Arg474His).
Epilepsy of infancy with migrating focal seizures was 
the most common electroclinical syndrome, present in 18 
patients (66.7%, 18/27). Four children had an unclassified 
EOEE, three children were diagnosed with West syndrome, 
and two children were diagnosed with ADSHE at some point. 
Three children have had more than one electroclinical phe-
notype throughout their trajectories; Cases 3 and 4 initially 
presented with EIMFS evolving to West syndrome, whereas 
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case 22's phenotype was initially consistent with unclassi-
fied EOEE, but the patient later developed ADSHE. Table 1 
summarizes the demographics, relevant clinical information, 
KCNT1 variant details, and neuroimaging findings.
Focal impaired awareness motor (tonic or with tonic com-
ponent) seizures were the most common seizure type (48.1%, 
13/27) observed in our cohort. In addition, a variety of other 
seizures were also observed, such as focal impaired aware-
ness nonmotor (behavioral arrest, autonomic, emotional), 
focal impaired awareness motor (hyperkinetic, clonic), gen-
eralized tonic, generalized tonic-clonic, generalized myoc-
lonic-tonic-clonic, generalized myoclonic, and generalized 
absence seizures (atypical). Estimated current seizure fre-
quency reported by caregivers was markedly variable at the 
time of data collection, with three patients (11.1%, 3/27) 
having >500 seizures/mo, nine patients (33.4%, 9/27) hav-
ing >100 up to 500 seizures/mo, three patients (11.1%, 3/27) 
having >50 up to 100 seizures/mo, seven patients (26%, 7/27) 
having 10 to 50 seizures/mo, and five patients (18.5%, 5/27) 
having <10 seizures/mo. None of the caregivers reported sei-
zure freedom.
The presence of developmental plateauing, EIMFS, and 
seizure burden were not associated with a specific genetic 
variant. Five children harboring c.2800G>A; p.Ala934Thr 
were compared with the rest of the cohort with respect to the 
presence of developmental plateauing (P = .13), phenotype 
consistent with EIMFS (P = .48), and estimated seizure fre-
quency > 500 per month (P = .22). In addition, four children 
harboring c.862G>A; p.Gly288Ser were compared with the 
rest of the cohort with respect to the presence of developmen-
tal plateauing (P = .93), phenotype consistent with EIMFS 
(P = .44), and estimated seizure frequency (P = .38). There 
were no significant differences between the genotypes ana-
lyzed compared with the rest of the cohort with respect to the 
aforementioned characteristics. The most common phenotype 
seen in our cohort consisted of nonambulatory (92.3%, 24/26; 
unavailable data in one patient), nonverbal (88%, 22/25; un-
available data in two patients), hypotonic (74%, 20/27), and 
spastic (48.1%, 13/27) patients, with acquired microcephaly 
(65.3%, 17/26; unavailable data in one patient) and cortical 
visual impairment (60%, 15/25; unavailable data in two pa-
tients). Only five children (18.5%, 5/27) were diagnosed with 
involuntary movements (see Table 1).
Brain MRI was abnormal in the majority of children 
(59.3%, 16/27). The most common findings were delayed 
myelination (68.7%, 11/16; or 40.7%, 11/27 of all patients) 
and thin corpus callosum (43.7%, 7/16; or 26%, 7/27 of all pa-
tients), usually but not always accompanied by brain atrophy 
(37.5%, 6/16; or 22%, 6/27 of all patients). The presence of 
an abnormality in the brain MRI was further evaluated in the 
two most common genetic variants in comparison with the 
rest of the cohort. There was no correlation between the pres-
ence of an abnormality in patients with specific genotypes in 
comparison with the rest of the cohort (ie, c.2800G>A; p.Al-
a934Thr vs other patients, P = .97; c.862G>A; p.Gly288Ser 
vs other patients, P = .68).
Systemically, these children often had constipation 
(40.7%, 11/27), gastroesophageal reflux disease (33.4%, 
9/27), and aspiration pneumonia (33.4%, 9/27). Only one 
child (Case 7) had a cardiac malformation (ventricular septal 
defect) and supraventricular ectopic activity.
Table  2 shows the current antiepileptic drugs (AEDs), 
number of total AEDs tried for each patient, alternative thera-
pies and estimated response for each, and final disposition for 
each patient. Twenty-three children are still under follow-up 
(85.2%, 23/27), and four have passed away (14.8%, 4/27). 
Cause of death was due to complications of systemic diseases 
(n = 1), progression of illness (n = 1), and redirection of the 
goal of care (n = 2). There were no reports of sudden unex-
pected death in epilepsy (SUDEP). Of the 23 children being 
followed, the number of current AEDs in use ranged from 
one to five (mean = 2.7, SD = 1.2, median = 2). Including 
the patients who died, the total number of AEDs tried ranged 
from three to 16 (mean = 7.4, SD = 3.1, median = 7). Given 
the high number of medications tried in a relatively short 
period of time and the subjective nature of responses, along 
with a variety of different combinations, we were unable to 
identify one or two AEDs that were particularly effective in 
controlling seizures. Eleven patients were tried on quinidine, 
with doses ranging from 20 to 60 mg/kg/d (mean = 35.9 mg/
kg/d, SD = 11.1, median = 40 mg/kg/d) and duration of ther-
apy from 1 to 28 months (mean = 9.1 months, SD = 9.5, me-
dian = 4 months). As per caregivers, estimated response was 
marked or some improvement in five (45.4%, 5/11), but there 
was no response whatsoever in six children (54.6%, 6/11). 
Five children (45.4%, 5/11) developed QTc prolongation 
while on quinidine, but none discontinued therapy for this 
reason. Irritability and vomiting were reported in one child 
each. The age at administration of quinidine ranged from 2 
to 37  months (mean = 11.4  months, SD = 9.8, median = 
8 months). There was no statistically significant correlation 
between responses to quinidine and the earlier age at onset of 
therapy (rs = 0.22917, P [2-tailed] = .49).
CBD was used in seven patients (26%, 7/27), with highly 
variable doses ranging from 0.25 to 10  mg/kg/d (mean = 
6 mg/kg/d, SD = 4.4, median = 7.5 mg/kg/d). Estimated re-
sponse was reported as marked or some improvement in five 
children (71.4%, 5/7) and minimal in two (28.6%, 2/7). CBD 
was well tolerated in all patients, with no side effects reported 
by the caregivers. Diet therapies were tried in 14 patients 
(51.8%, 14/27), which included the ketogenic diet in 12 and 
low glycemic index diet in two. Eight children (57.2%, 8/14) 
had marked or some improvement, and six (42.8%, 6/14) had 
minimal or no improvement. There was no statistically sig-
nificant correlation when children harboring c.2800G>A; 
p.Ala934Thr or c.862G>A; p.Gly288Ser were compared 
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T A B L E  2  Current and past therapies, estimated response to alternative treatments, and final disposition















estimated responsea Final disposition
1 CLB, LRZ, PB 6/9 KD; 9; 4:1; marked Y; 1; 40 mg/kg/d; nil Y; 8; 10 mg/kg/d; 
some
Under follow-up
2 PB 5/6 KD; 6; 3.75:1; nil Y; 3; 60 mg/kg/d; nil Y; 1; 10 mg/kg/d; 
some
Under follow-up
3 LEV, PB 7/9 KD; 49; 4.25:1; 
marked
Not tried Y; 31; 7.5 mg/kg/d; 
marked
Under follow-up
4 LEV 2/3 KD; 46; 4:1; marked Not tried Y; 8; 0.5 mg/kg/d; 
marked
Under follow-up
5 N/A 9/9 Not tried Not tried Not tried Died (systemic 
illness)
6 LEV, VPA 1/3 Not tried Not tried Not tried Under follow-up
7 LEV, TPM 2/4 Not tried Not tried Not tried Under follow-up
8 PB, TPM 2/4 Not tried Not tried Not tried Under follow-up
9 CLB, OXC, 
TPM
4/7 KD; 21; 4:1; marked Y; 19; 20 mg/kg/d; 
some
Not tried Under follow-up
10 CLB, LEV, PB 4/7 KD; 31; 3:1; marked Y; 3; 40 mg/kg/d; 
marked
Not tried Under follow-up
11 CBZ, CLN 10/12 KD; 1; 3:1; nil Y; 9; 40 mg/kg/d; some Y; 9; 10 mg/kg/d; 
marked
Under follow-up
12 GBP, LEV, 
TPM, VGB
2/6 Not tried Not tried Not tried Under follow-up
13 CLB, LEV, PB, 
VPA
3/7 Not tried Not tried Not tried Under follow-up
14 LEV, PER, 
TPM, VPA
6/10 KD; 0.5; 3:1; some Not tried Not tried Under follow-up
15 CLB, LEV, PB 3/6 LGID; 30; unknown; 
some
Y; 28; 40 mg/kg/d; 
marked
Not tried Under follow-up
16 CLB, PB, DPH, 
TPM
7/11 LGID; 3; N/A; 
minimal
Y; 22; 20 mg/kg/d; 
marked
Not tried Under follow-up
17 DZP 5/6 KD; unknown; 3.75:1; 
marked
Not tried Not tried Under follow-up
18 CLB, LEV 4/6 Not tried Not tried Not tried Under follow-up
19 ACTH, CLB, 
LEV, PB, 
TPM
6/11 KD; 9; 3:1; minimal Not tried Y; unknown; 4 mg/
kg/d; nil
Under follow-up
20 N/A 6/6 Not tried Y; 4; 30 mg/kg/d; nil Not tried Died (disease 
progression and 
redirection of care)
21 PIR, VPA 8/10 Not tried Not tried Not tried Under follow-up
22 CBZ, CLB, 
TPM
3/7 Not tried Not tried Not tried Under follow-up
23 CBZ, CLN, 
LEV, TPM, 
VPA
11/16 Not tried Not tried Not tried Under follow-up
24 LEV 9/10 Not tried Not tried Not tried Under follow-up
(Continues)
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with the rest of the cohort with respect to treatment response 
to quinidine, CBD, or diet therapy.
4 |  DISCUSSION
This observational study is one of the largest interna-
tional cohorts examining pediatric patients diagnosed with 
KCNT1-related epilepsy. There was no selection bias with 
respect to the phenotypic characterization of this patient 
sample, given that the essential criterion was related to the 
presence of pathogenic or likely pathogenic KCNT1 vari-
ants. Some may argue that the presence of ADSHE could 
be underestimated due the cutoff age of the inclusion cri-
teria, but we believe our data reflect the current circum-
stances of clinicians dealing with KCNT1-related epilepsy 
in infancy and childhood. The 17-month gap between first 
seizures (mean age at onset of seizures = 1.7 months) and 
diagnosis of KCNT1-related epilepsy (mean age at diagno-
sis = 18.8 months) in our cohort reflects the true odyssey for 
families and physicians alike.
As previously reported by different authors, KCNT1 
pathogenic variants are highly pleiotropic and associated 
with a variety of phenotypes.8,18,27 In our study, two-thirds 
of patients presented with EIMFS; however, unclassified 
EOEE, West syndrome, and ADSHE were also present, sim-
ilar to previous reports. Further analysis of recurrent variants 
and seizure burden related to specific genotypes produced no 
significant results, reinforcing the variability in gene expres-
sion and high pleiotropy of KCNT1 pathogenic variants.
However, our data obtained from 27 affected children en-
abled us to refine the phenotypic characterization, which may 
help in earlier recognition of these patients; early onset of 
tonic seizures that are medically refractory, with plateauing 
of milestones, hypotonia, cortical visual impairment, and ac-
quired microcephaly should promptly raise a heightened index 
of suspicion for KCNT1-related epilepsy, likely manifesting 
as EIMFS or unclassified EOEE. Obviously, other seizure 
types and developmental trajectories can be seen. Similar to 
our results, the high prevalence of acquired microcephaly was 
also noted by Kuchenbuch et al to be as high as 90% after 3 
years of follow-up.28 Given the cross-sectional nature of our 
study, we were not able to delineate different phases experi-
enced by EIMFS patients over time, recently described as the 
stormy phase, stabilization period, and chronic phase.28
Somatic mosaicism (ie, DNA alteration occurring at the 
postzygotic stage) may also contribute to the phenotypic 
heterogeneity seen in some epilepsy genes. As previously 
demonstrated for “de novo” epileptic encephalopathies, 8.3% 
of parents have mosaicism of their child's pathogenic vari-
ant, particularly when there is parental history of seizures.29 
Interestingly, the high prevalence of positive family history of 
seizures (~30%) in our patients and in another study28 might 
indicate the need for future research focused on relatives of 
patients with KCNT1-related epilepsy.
Although we often consider that neuroimaging is normal 
in the genetic epileptic encephalopathies, our data reinforce 
that in KCNT1-related epilepsies brain MRI can be abnormal 
(59% of our children). From those with abnormal imaging, 
we found that delayed myelination, thin corpus callosum, and 
brain atrophy were the most common findings, albeit some of 
these abnormalities (ie, delayed myelination and brain atro-
phy) are likely to depend on whether the neuroimaging was 
obtained at earlier or later stages of the disease. One of our 
patients (Case 27) was found to have areas of indistinctness 
in the gray-white matter interface, which could suggest an 
underlying malformation of cortical development, as recently 
described in patients with KCNT1 pathogenic mutations and 
ADSHE.11
Given the expression of KCNT1 in muscle tissue, gonads, 
and the pituitary gland, it has been proposed that KCNT1 mu-
tations can be involved in cardiac anomalies, SUDEP, and 















estimated responsea Final disposition
25 N/A 11/11 KD; 1; 3.5:1; nil Y; 2; 35 mg/kg/d; nil Not tried Died (systemic 
illness)
26 CLN, LEV 2/4 Not tried Y; 9; 30 mg/kg/d; nil Not tried Under follow-up





Abbreviations: ACTH, adrenocorticotropic hormone; AED, antiepileptic drug; CBD, cannabidiol; CBZ, carbamazepine; CLB, clobazam; CLN, clonazepam; DPH, 
phenytoin; DZP, diazepam; GBP, gabapentin; KD, ketogenic diet (classical); LEV, levetiracetam; LIGD, low glycemic index diet; LRZ, lorazepam; N/A, not 
applicable; OXC, oxcarbazepine; PB, phenobarbital; PER, perampanel; PIR, piracetam; TPM, topiramate; VGB, vigabatrin; VPA, valproate; Y, yes.
aEstimated response scale: marked improvement, >50% reduction in seizures; some improvement, 25%-50% reduction in seizures; minimal, <25% reduction in 
seizures; nil, no change in seizure frequency. 
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precocious puberty.5,27,28 One of our patients (Case 7) was di-
agnosed with a ventricular septal defect and supraventricular 
ectopic activity. However, unlike in the other reported cases, 
neither SUDEP nor precocious puberty was reported in our 
series, possibly due to limited long-term follow-up of this co-
hort. A cross-sectional study including older patients as well 
as long-term follow-up assessments could help identify pre-
cocious puberty and perhaps SUDEP if these conditions are 
related to KCNT1-related epilepsy.
Poor response to AEDs is a common characteristic among 
KCNT1-related epilepsy patients regardless of the pheno-
type. Not different from other studies,18,28 our patients were 
exposed to several AEDs over time (mean = 7.4, SD = 3.1), 
with no seizure freedom achieved. Moreover, more than one-
half (55%, 15/27) reported >50 seizures monthly. These data 
promptly led clinicians and families to look for alternative 
treatments. After some case reports successfully reported 
treating KCNT1-related epilepsy with quinidine,12,13 sev-
eral authors unfortunately have not been able to reproduce 
the same outcomes.14‒17 In addition, a small blinded, pla-
cebo-controlled, crossover trial that included six ADSHE 
patients did not show a significant difference in seizure fre-
quency during the quinidine phase compared with placebo, 
and paroxysmal arousals were similarly unchanged. There 
were no patients achieving the 50% reduction mark.30
In our retrospective analysis, nearly 50% of (5/11) pa-
tients had marked or some seizure reduction with quinidine. 
Twenty-seven percent (3/11) reported >50% seizure reduc-
tion, and 18.1% (2/11) reported from 25% to 50% seizure 
reduction. Our findings were similar to those from the larg-
est cohort of KCNT1-related epilepsy, which evaluated 20 
patients taking quinidine and found nearly 50% (9/20) of 
patients with some response, including 20% of patients hav-
ing at least 50% seizure reduction.18 Neither seizure freedom 
nor worsening of seizures was reported in our patients. In 
addition, we were not able to establish statistical correlation 
suggesting an age-dependent response to quinidine, as previ-
ously reported in the literature.15
Other than quinidine, we were also able to record rea-
sonable efficacy of diet therapy and CBD. When taking 
into consideration patients exposed to diet therapies, 43% 
(6/14) had >50% seizure reduction. Analyzing the response 
to the ketogenic diet (not including the low glycemic index 
diet), half of the patients (6/12) had >50% seizure reduc-
tion. Reasonable response to the ketogenic diet has also 
been reported, with a response rate of 31% (9/29) as per 
caregivers and physicians.18 For those who responded well 
to CBD, two of three were previously on the ketogenic diet, 
making any conclusions on the CBD efficacy merely specu-
lative. In addition, the small number of patients on CBD 
and the lack of consistency of the dosage prescribed (from 
0.25 to 10 mg/kg/d) limit our capacity to draw meaningful 
conclusions.
In addition to the limitations related to our study method, 
which include missing data and lack of longitudinal fol-
low-up, our study is hampered by the limited number of pa-
tients for subset analysis. This is difficult to overcome when 
gathering data in a rare condition. Parental reports of seizure 
frequency (sometimes hard to recognize due to subtle man-
ifestations, or sometimes overcalled due to the presence of 
abnormal movements and behavioral issues) and the lack of 
standardized use of some therapies (ie, CBD and quinidine 
doses) are further limitations of our study. Moreover, with 
our current data, it is still unclear whether somatic mutations 
are particularly relevant in KCNT1-related epilepsy. The low 
level of parental mosaicism could be underestimated given 
that the great majority of parental testing in our study was 
through Sanger sequencing and not through next generation 
sequencing analysis.31
In summary, through international collaboration and in 
comparison with previous literature data, we were able to 
delineate the common aspects within this highly pleiotropic 
entity, KCNT1-related epilepsy: early onset refractory tonic 
seizures, likely (but not exclusively) manifesting as EIMFS 
or unclassified EOEE, along with milestones plateauing, 
hypotonia, cortical visual impairment, and acquired micro-
cephaly. Supportive but not mandatory neuroimaging find-
ings included delayed myelination, thin corpus callosum, 
brain atrophy, and rarely malformations of cortical develop-
ment. Despite the lack of satisfactory evidence, alternative 
treatments such as the ketogenic diet and quinidine seem to 
be well tolerated and may help achieve seizure reduction of 
>50%.
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